Taken into account that these two clinical entities can progress to liver fibrosis or even cirrhosis, the dynamic evaluation of syndecan-1 serum levels in patients with these chronic disorders seems reasonable. This evidence concerns the gene SDC1 and Hepatic fibrosis.